- Selecta Biosciences (NASDAQ:SELB) reports that the National Cancer Institute informed it of a patient death from pneumonitis in a Phase 1 clinical trial evaluating combination product SEL-403 in patients with solid tumors. The investigator believes the fatality was probably related to SVP-Rapamycin, one of the components of SEL-403 (the other is LMB-100).
- A total of four patients have been dosed in the study. In addition to the death, one participant experienced a serious adverse event, pericardial effusion, a potential side effect of immunotoxin therapies targeting mesothelin. No patients are active in the study and enrollment has been stopped.
- SVP-Rapamycin is also a component of SEL-212 (together with pegsiticase), currently being investigated in a Phase 2 study in symptomatic gout. There have been no cases of pneumonitis among the 150 participants dosed to date. Interim data will be presented at ACR/ARHP next week.
- Now read: The Investment Case For Selecta Biosciences
Original article